miR-21在川崎病急性期患者血清中的表达及其临床意义

Abstract
Figure/Table
References (0)
Related Citation (11)

Download: PDF (1327 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To study the expression of miR-21 in the serum of patients with Kawasaki disease and its clinical significance. Methods: Thirty-three cases of Kawasaki disease and 15 healthy control were collected from the Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical University in 2014 and 2015. With cel-miR-39 as the external reference gene, the expression of miR-21 was detected with real-time quantitative PCR, and its significance as a marker in diagnosis was evaluated by ROC curve. Results: The expression of miR-21 in serum of KD patients was significantly higher than that in the healthy control group (P<0.05), and return to normal level after treatment. ROC curve indicated miR-21 had a sensitivity of 84.6% and a specificity of 71.4% for distinguishing KD patients from healthy children with an area under the curve (AUC) were 0.736 (95%CI: 0.531～0.941). Further analysis of the clinical pathological features indicated that the level of serum miR-21was associated with PLT. Conclusion: Serum miR-21 level is significantly elevated in KD patients, it may be used as a potential biomarker in diagnosis of KD.

Key words： Kawasaki disease microRNA-21 disease diagnosis

Received: 22 January 2016

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIA Lianhong
	PAN Lulu
	LU Jiacheng
	GENG Zhimin
	WU Rongzhou
	CHU Maoping.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2016/V46/I4/254

[1] 杜忠东, 梁璐, 孟晓萍, 等. 1995-1999年北京住院小儿川崎病流行病学调查[J]. 中华医学杂志, 2003, 83(21): 38-42.
[2] 张永兰, 杜忠东, 赵地, 等. 2000-2004年北京川崎病住院患儿流行病学调查[J]. 实用儿科临床杂志, 2007, 22(1): 12-15.
[3] YIM D, CURTIS N, CHEUNG M, et al. An update on Kawasaki disease II: clinical features,diagnosis, treatment and outcomes [J]. J Paediatr Child Health, 2013, 49(8): 614-623.
[4] AYUSAWA M, SONOBE T, UEMURA S, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition)[J]. Pediatr Int, 2005, 47(2): 232-234.
[5] NEWBURGER J W, TAKAHASHI M, GERBER M A, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association[J]. Pediatrics, 2004, 114(6): 1708-1733.
[6] FISH J E, SANTORO M M, MORTON S U, et al. miR-126 regulates angiogenic signaling and vascular integrity[J]. Dev Cell, 2008, 15(2): 272-284.
[7] MITCHELL P S, PARKIN R K, KROH E M, et al. Circulation microRNAs as stable blood-based markers for cancer detection[J]. Proc Natl Acad Sci U S A, 2008, 105(30): 10513-10518.
[8] HUANG Z, HUANG D, NI S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer[J]. Int J Cancer, 2010, 127(1): 118-126.
[9] SHIMIZU C, KIM J, STEPANOWSKY P, et al. Differential expression of miR-145 in children with Kawasaki disease[J]. PloS One, 2013, 8(3): e58159.
[10] YUN K W, LEE J Y, YUN S W, et al, et al. Elevated serum level of microRNA (miRNA)-200c and miRNA-371-5p in children with Kawasaki disease [J]. Pediatr Cardiol, 2014, 35(5): 745-752.
[11] ROWLEY A H, PINK A J, REINDEL R, et al.A study of cardiovascular miRNA biomarkers for Kawasaki disease[J]. Pediatr Infect Dis J, 2014, 33(12): 1296-1299.
[12] NI F F, LI C R, LI Q, et al. Regulatory T cell microRNA expression changes in children with acute Kawasaki disease[J]. Clin Exp Immunol, 2014, 178(2): 384-393.
[13] ZHOU J, WANG K C, WU W, et al. MicroRNA-21 targets peroxisome proliferators-activated receptor-alpha in an autoregulatory loop to modulate flow-induced endothelial inflammation [J]. Proc Natl Acad Sci U S A, 2011, 108(25):10355-10360.
[14] LI Y, YAN L, ZHANG W, et al. MicroRNA-21 inhibits platelet-derived growth factor-induced human aortic vascular smooth muscle cell proliferation and migration through targeting activator protein-1[J]. Am J Transl Res, 2014, 6(5):507-516.
[15] ZUO K, LI M, ZHANG X, et al. MiR-21 suppresses endothelial progenitor cell proliferation by activating the TGF-beta signaling pathway via downregulation of WWP1[J]. Int J Clin Exp Pathol, 2015, 8(1): 414-422.
[16] RAITOHARJU E, LYYTIKAINEN L P, LEVULA M, et al. miR-21, miR-210, miR-34a, and miR-146ab are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study[J]. Atherosclerosis, 2011, 219(1): 211-217.
[17] WANG M, LI W, CHANG G Q, et al. MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities[J]. Arterioscler Thromb Vasc Biol, 2011, 31(9): 2044-2053.
[18] SARKAR J, GOU D, TURAKA P, et al. MicroRNA-21plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration[J]. Am J Physiol Lung Cell Mol Physiol, 2010, 299(6): L861-L871.
[19] JI R, CHENG Y, YUE J, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation [J]. Circ Res, 2007, 100(11): 1579-1588.
[20] ROY S, KHANNA S, HUSSAIN S R, et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue[J]. Cardiovasc Res, 2009, 82(1): 21-29.
[21] CHENG Y, ZHU P, YANG J, et al. Ischaemic preconditioning-regulated miR-21 protects heart against ischaemiareperfusion injury via anti-apoptosis through its target PDCD4[J]. Cardiovasc Res, 2010, 87(3): 431-439.
[22] 褚茂平, 胡晨, 周爱华, 等. 川崎病血清特异相关miR-23a对人脐静脉内皮细胞生长及迁移的影响[J]. 温州医科大学学报, 2015, 45(5): 321-326.
[23] 褚茂平, 周爱华, 胡晨, 等. miR-130a和miR-125b在川崎病外周血细胞中的表达及意义[J]. 浙江医学, 2015, 37(5):357-362.